EGFR and neoplasm: Here, we revealed the feasibility of serial sampling of tissue and blood to detect immune cell alterations in the tumor microenvironment and in circulation that may underlie antitumor activity and toxicity with EGFR-directed therapy plus PD(L)1 inhibition.